The Current Ratio as of September 2024 (TTM) for NeuBase Therapeutics, Inc. (NBSE) is 2.87

According to NeuBase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.87. This represents a change of -45.78% compared to the average of 5.30 of the last 4 quarters.

NeuBase Therapeutics, Inc. (NBSE) Historical Current Ratio (quarterly & annually)

How has NBSE Current Ratio performed in the past?

The mean historical Current Ratio of NeuBase Therapeutics, Inc. over the last ten years is 6.57. The current 2.87 Current Ratio has changed 4.27% with respect to the historical average. Over the past ten years (40 quarters), NBSE's Current Ratio was at its highest in in the June 2021 quarter at 19.18. The Current Ratio was at its lowest in in the March 2017 quarter at 1.43.

NeuBase Therapeutics, Inc. (NBSE) Current Ratio by Quarter and Year

Discovering the peaks and valleys of NeuBase Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

NeuBase Therapeutics, Inc. (NBSE) Average Current Ratio

How has NBSE Current Ratio performed in the past?

The current Current Ratio of NeuBase Therapeutics, Inc. (NBSE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

NeuBase Therapeutics, Inc. (NBSE) Current Ratio vs. Peers

How is NBSE’s Current Ratio compared to its peers?

NeuBase Therapeutics, Inc.’s Current Ratio is less than Immix Biopharma, Inc. (7.00), greater than CNS Pharmaceuticals, Inc. (0.31), greater than eFFECTOR Therapeutics, Inc. (1.03), greater than Navidea Biopharmaceuticals, Inc. (0.56), greater than Sonnet BioTherapeutics Holdings, Inc. (1.65), less than Kiromic BioPharma, Inc. (0), greater than ZyVersa Therapeutics, Inc. (0.35), greater than YS Biopharma Co., Ltd. (0.06), greater than BiomX Inc. (0.94), less than Landos Biopharma, Inc. (4.80), less than Apexigen, Inc. (4.43), greater than Angion Biomedica Corp. (0.82), greater than Monte Rosa Therapeutics, Inc. (1.74), less than NewAmsterdam Pharma Company N.V. (6.56), less than Inventiva S.A. (9.83), greater than Cullinan Oncology, Inc. (0.95), less than Compass Therapeutics, Inc. (28.87), less than null (40.74),

Build a custom stock screener for NeuBase Therapeutics, Inc. (NBSE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeuBase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

NeuBase Therapeutics, Inc. (NBSE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like NeuBase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.